Geode Capital Management LLC boosted its stake in Lipocine Inc. (NASDAQ:LPCN – Free Report) by 6.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 57,464 shares of the specialty pharmaceutical company’s stock after acquiring an additional 3,248 shares during the period. Geode Capital Management LLC owned 1.07% of Lipocine worth $280,000 as of its most recent filing with the SEC.
Lipocine Price Performance
Shares of NASDAQ LPCN opened at $3.41 on Friday. The stock has a market capitalization of $18.24 million, a PE ratio of -4.49 and a beta of 1.51. Lipocine Inc. has a one year low of $2.75 and a one year high of $11.79. The business’s fifty day moving average price is $3.22 and its 200-day moving average price is $4.21.
Analysts Set New Price Targets
Separately, StockNews.com initiated coverage on shares of Lipocine in a report on Thursday. They issued a “hold” rating on the stock.
Lipocine Company Profile
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Further Reading
- Five stocks we like better than Lipocine
- What is the Dogs of the Dow Strategy? Overview and Examples
- Magnificent 7 Stocks Send a Dire Warning to Markets
- How to invest in marijuana stocks in 7 steps
- Why Spotify Stock Still Has Room to Run in 2025
- A Deeper Look at Bid-Ask Spreads
- Buy the Dip: Top Tech Stocks Analysts Say Are Undervalued
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.
